Stocks and Investing Stocks and Investing
Wed, July 5, 2023

Kostas Biliouris Upgraded (BMRN) to Buy and Held Target at $102 on, Jul 5th, 2023


Published on 2024-10-28 04:37:58 - WOPRAI, Kostas Biliouris
  Print publication without navigation


Kostas Biliouris of BMO Capital, Upgraded "BioMarin Pharmaceutical Inc." (BMRN) to Buy and Held Target at $102 on, Jul 5th, 2023.

Kostas has made no other calls on BMRN in the last 4 months.



There are 10 other peers that have a rating on BMRN. Out of the 10 peers that are also analyzing BMRN, 4 agree with Kostas's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Whitney Ijem of "Canaccord Genuity" Maintained at Hold with Decreased Target to $104 on, Monday, July 3rd, 2023
  • Andreas Argyrides of "Wedbush" Maintained at Hold with Increased Target to $73 on, Friday, June 30th, 2023
  • David Lebowitz of "Citigroup" Maintained at Hold with Decreased Target to $96 on, Friday, June 30th, 2023
  • Luca Issi of "RBC Capital" Reiterated at Hold and Held Target at $100 on, Thursday, April 27th, 2023


These are the ratings of the 6 analyists that currently disagree with Kostas


  • Joel Beatty of "Baird" Reiterated at Buy and Held Target at $127 on, Friday, June 30th, 2023
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $140 on, Friday, June 30th, 2023
  • Tiago Fauth of "Credit Suisse" Initiated at Buy and Held Target at $120 on, Wednesday, June 14th, 2023
  • Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Decreased Target to $120 on, Thursday, April 27th, 2023
  • Christopher Raymond of "Piper Sandler" Maintained at Buy with Decreased Target to $125 on, Thursday, April 27th, 2023
  • William Pickering of "Bernstein" Initiated at Sell and Held Target at $81 on, Tuesday, March 21st, 2023
Contributing Sources